NCT02738450View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Down Syndrome
Interventions
BIOLOGICAL

ACI-24 low dose

ACI-24 administered as a sterile suspension in PBS via s.c. injection.

BIOLOGICAL

ACI-24 high dose

ACI-24 administered as a sterile suspension in PBS via s.c. injection.

BIOLOGICAL

Placebo

Placebo is a standard PBS sterile solution administrated via s.c. injection.

Trial Locations (4)

21224

Johns Hopkins University, Baltimore

85013

St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix

92037-1712

UCSD Adult Down Syndrome Program, La Jolla

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

AC Immune SA
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Alzheimer's Disease Cooperative Study (ADCS)

OTHER

collaborator

LuMind IDSC Foundation

OTHER

lead

AC Immune SA

INDUSTRY